Profit

NSE Symbol: | BSE Code: | ISIN: | Sector:

  • Add to Portfolio
  • Add to Watchlist
  • Add to Alert
  • Add to Message
Add to Portfolio
NSE
423.50
Change Change %
4.65 1.11%

Updated:27 Oct, 2020, 15:59 PM IST

BSE
423.20
Change Change %
4.90 1.17%

Updated:27 Oct, 2020, 16:01 PM IST

Cadila Healthcare (CHL), incorporated in 1995, is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the state of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti–infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The company focuses on providing high quality, appropriately priced products to its customers and supports all these with dedicated customer service. Cadila Pharmaceuticals has a multicultural, multilingual and multinational workforce of more than four thousand employees including over two hundred people outside India in forty–nine countries of Africa, CIS, Japan and USA.

The company?óÔé¼Ôäós headquarter is located at Ahmedabad. CHL operates eight manufacturing facilities out of which four formulation plants are located at Ahmedabad, Goa, Baddi and Sikkim. The company has state–of–the–art manufacturing facilities conforming to the most stringent international cGMP norms vis–?â?á–vis WHO–GMP, WHO, Geneva (GDF site for Anti– TB), TGA Australia (PIC/S), USFDA, UK– MHRA, MCC–South Africa, ISO 9001 and ISO 14001. Spread over hundred acres of land, Cadila Pharmaceuticals?óÔé¼Ôäó manufacturing facility at Dholka is the cynosure of all eyes, well equipped with world–class production facilities. The company?óÔé¼Ôäós two Active Pharmaceutical Ingredients units at Ankleshwar manufacture a wide–range of APIs and intermediates including three USFDA certified products. The manufacturing facility at Samba, near Jammu, started its commercial operations in August 2006. The first overseas formulation manufacturing facility of Cadila                                       Pharmaceuticals Ltd. has commenced its operations in Ethiopia.

The Zydus Cadila Group operates in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.

The company has in–licensing alliances with global multinationals such as Schering AG, Boehringer Ingelheim, Viatris, etc.

Products

Formulations– The company is one of the leading player that caters to various therapeutic areas such as cardiovascular, gastrointestinal, respiratory, pain management, CNS, anti–infectives, oncology, neurosciences, dermatology and nephrology segments.

CHL manufactures its formulations in various forms such as oral, vaccines and inhalers. The company has portfolio of 200 products and created brands like Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia and Mifegest, to name a few.

Consumer product division– This is a healthcare division that has brands like Sugar Free, Nutralite and Everyuth. Its sugar–free has range of sugar substitutes; Nutralite is cholesterol–free bread spread and Everyuth has range of skincare products.

Milestones:

July 27, 2011: Cadila acquired German company, Bremer Pharma GmbH, from ICICI Venture, gains global footprint in animal healthcare business

October 14, 2010: Cadila launches Pramipexole Tablets in the US market

May 12, 2010: Cadila to launch India?óÔé¼Ôäós 1st H1N1 vaccine

March 30, 2009: Cadila announces research collaboration to discover and develop new cardiovascular medicines 

Top
Listen to the latest songs, only on JioSaavn.com